



25 February 2019

ASX Announcement

Principal Investigator appointed for Bisantrene trial

25 February 2019: Race Oncology Limited ('RAC') is pleased to announce that Dr Roland Walter has agreed to be the Principal Investigator for the US registration trial for Bisantrene.

Roland B. Walter, MD PhD MS, is a leading international haematologist and AML expert, based at the Fred Hutchinson Cancer Research Center in Seattle.

"We are fortunate to have a global AML leader like Dr Walter to lead the multinational Bisantrene study," said Race Oncology CEO, Peter Molloy.

The trial is planned to be a Phase 2/3 study in support of the US FDA registration of Bisantrene for the treatment of relapsed/refractory AML (Acute Myeloid Leukaemia).

Trial commencement is subject to the filing by Race of an IND (Investigational New Drug application) with the FDA.

"We remain on track to see the IND filed by the end of March," said Mr Molloy. "It will be an important milestone for the Company."

Commencement of the trial is also subject to funding. Through an agreement with Biosynergy Partners, Race has been engaged in discussions with potential partners about funding of the trial.

About Professor Roland Walter

Dr Walter currently holds several positions including Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center; Associate Professor of Medicine, Division of Hematology/Department of Medicine, University of Washington; and Adjunct Associate Professor, Departments of Pathology and Epidemiology, University of Washington. He is also a current Leukemia & Lymphoma Society Scholar in Clinical Research. Dr Walter's clinical and translational research program is focused on AML, primarily on the preclinical and early clinical development of novel targeted therapeutics. Dr Walter is extensively published, has received numerous honours and awards, and has editorial responsibilities at key journals including *Blood Reviews*, *Blood Advances* and *International Journal of Hematologic Oncology*.



About Race Oncology (RAC.ASX)

Race Oncology is a specialty pharmaceutical company whose business model is to pursue later-stage drug assets in the cancer field that have been overlooked by big pharma. The company's first asset is Bisantrene, a chemotherapy drug, which was the subject of more than 40 clinical studies during the 1980s and 1990s before the drug was abandoned after a series of pharmaceutical mergers. Bisantrene has compelling Phase II data in acute myeloid leukaemia (AML) and Race is seeking to gain US FDA approval for Bisantrene for AML under the accelerated 505(b)(2) regulatory pathway. Bisantrene is the subject of two recently granted US patents and has been awarded US Orphan Drug designation and a Rare Paediatric Disease designation.

Media contact:

Heidi Cuthbert, +61 411 272 366;
E: heidi.cuthbert@multiplier.com.au